MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

Home・Aandelen Lijst・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

40.98 -2.82

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

42.15

Belangrijke statistieken
By Trading Economics
Inkomsten	-6.2M -91M
Winstmarge	-867.293
Werknemers	316
EBITDA	4M -90M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+27.99% upside

Dividenden
By Dow Jones
Volgende Winsten	26 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-639K 3.2B
Vorige openingsprijs	43.8
Vorige sluitingsprijs	40.98

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

34.81 / 38.24 Steun & Weerstand

Xenon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 jan 2026, 23:08 UTC

Acquisities, Fusies, Overnames

Rio Tinto, Glencore in Talks to Form World's Biggest Miner -- 3rd Update

8 jan 2026, 21:39 UTC

Acquisities, Fusies, Overnames

Glencore, Rio Tinto Restart Merger Talks -- 2nd Update

8 jan 2026, 20:54 UTC

Acquisities, Fusies, Overnames

Glencore, Rio Tinto Restart Merger Talks -- Update

8 jan 2026, 20:44 UTC

Acquisities, Fusies, Overnames

Glencore, Rio Tinto Restart Merger Talks

8 jan 2026, 17:05 UTC

Acquisities, Fusies, Overnames

Chinese Anta Sports Products Offers to Buy Pinault Family's Stake in Puma, Reuters Says, Citing Unnamed Sources

8 jan 2026, 16:43 UTC

Belangrijke Marktbewegers

Babcock & Wilcox Shares Rise on Siemens Deal for Data Center Project

8 jan 2026, 23:44 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen -- Market Talk

8 jan 2026, 23:37 UTC

Marktinformatie

Gold Steady, Underpinned by Geopolitical Risks -- Market Talk

8 jan 2026, 22:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 jan 2026, 22:42 UTC

Marktinformatie

RBA Still Battling a Troubling Inflation Outlook, Says TD -- Market Talk

8 jan 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Glencore, Rio Tinto Confirm Early Merger Talks -- Barrons.com

8 jan 2026, 21:53 UTC

Winsten

These Stocks Moved the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 jan 2026, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

8 jan 2026, 21:10 UTC

Acquisities, Fusies, Overnames

Rio Tinto Says Current Expectation That Any Deal Would Involve Buying Glencore Via Scheme of Arrangement

8 jan 2026, 21:09 UTC

Marktinformatie

Oil Rises As Trump Said to Back Russia Sanctions Bill -- Market Talk

8 jan 2026, 21:09 UTC

Acquisities, Fusies, Overnames

Rio Tinto Confirms in Talks With Glencore Over Possible Merger

8 jan 2026, 20:21 UTC

Marktinformatie

U.S. Natural Gas Futures Down Despite Inventory Draw -- Market Talk

8 jan 2026, 19:44 UTC

Marktinformatie

Gold's Shine Masks Deep Drops in Canada Steel, Aluminum Exports -- Market Talk

8 jan 2026, 18:50 UTC

Marktinformatie

Mexico's Industrial Production Seen Lower in November -- Market Talk

8 jan 2026, 17:48 UTC

Winsten

These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8 jan 2026, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 jan 2026, 17:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

8 jan 2026, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

8 jan 2026, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 jan 2026, 16:45 UTC

Marktinformatie

Goldman Lifts 1H LME Copper Forecast -- Market Talk

8 jan 2026, 16:03 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 jan 2026, 16:03 UTC

Marktinformatie

Currency Markets Could Be Underpricing Medium-Term Risks -- Market Talk

8 jan 2026, 16:02 UTC

Marktinformatie

U.S. Natural Gas Inventories Fall As Expected -- Market Talk

8 jan 2026, 15:23 UTC

Acquisities, Fusies, Overnames

Paramount Defends Its Hostile Bid for Warner -- Update

Peer Vergelijking

Prijswijziging

Xenon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

27.99% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 53.91 USD 27.99%

Hoogste 60 USD

Laagste 44 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xenon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Gebaseerd op 13 analisten die aandelenratings hebben gegeven aan Xenon Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

34.81 / 38.24Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.